KALVISTA PHARMACEUTICALS INC's ticker is KALV and the CUSIP is 483497103. A total of 98 filers reported holding KALVISTA PHARMACEUTICALS INC in Q4 2021. The put-call ratio across all filers is 1.68 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $2,812,977 | +14.5% | 312,553 | 0.0% | 0.32% | -15.5% |
| Q1 2023 | $2,456,667 | +116164.4% | 312,553 | 0.0% | 0.37% | +17.6% |
| Q4 2022 | $2,113 | -100.0% | 312,553 | 0.0% | 0.32% | -56.4% |
| Q3 2022 | $4,535,000 | +47.4% | 312,553 | 0.0% | 0.73% | +12.2% |
| Q2 2022 | $3,076,000 | -33.2% | 312,553 | 0.0% | 0.65% | -36.8% |
| Q1 2022 | $4,607,000 | +11.4% | 312,553 | 0.0% | 1.03% | +7.4% |
| Q4 2021 | $4,135,000 | -24.2% | 312,553 | 0.0% | 0.96% | -33.4% |
| Q3 2021 | $5,454,000 | +0.4% | 312,553 | +37.9% | 1.44% | -24.0% |
| Q2 2021 | $5,431,000 | -1.4% | 226,671 | +5.7% | 1.89% | -13.8% |
| Q1 2021 | $5,510,000 | – | 214,467 | – | 2.20% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 1,810,246 | $17,432,669 | 7.30% |
| TCG Crossover Management, LLC | 3,395,495 | $32,698,617 | 4.82% |
| TANG CAPITAL MANAGEMENT LLC | 3,440,345 | $33,130,522 | 4.68% |
| VR Adviser, LLC | 2,916,667 | $28,087,503 | 2.96% |
| Frazier Life Sciences Management, L.P. | 3,238,859 | $31,190,212 | 2.07% |
| Nan Fung Group Holdings Ltd | 234,573 | $2,258,938 | 1.83% |
| DAFNA Capital Management LLC | 605,532 | $5,831,273 | 1.81% |
| Opaleye Management Inc. | 500,000 | $4,815,000 | 1.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 530,400 | $5,107,752 | 1.55% |
| MPM BioImpact LLC | 577,958 | $5,565,736 | 1.49% |